Acadia Pharma (ACAD): NUPLAZID 4Q Outlook - Piper Jaffray

October 3, 2016 6:38 AM EDT
Get Alerts ACAD Hot Sheet
Price: $27.12 +0.15%

Rating Summary:
    9 Buy, 5 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 21 | Down: 18 | New: 19
Trade ACAD Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Piper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on shares of Acadia Pharmaceuticals (NASDAQ: ACAD) and believes that the first full quarter postlaunch for NUPLAZID will meet his estimates. Unfortunately, his estimates are 20% of what the street is expecting. For 3Q, 4Q and 2017, the analyst's estimates are $0.7, $1.7 and $20.3 compared with consensus of $4.6, $10.2, and $103.4.

Street consensus looks similar to pre-2Q earnings, which makes sense given the street only has 1 month of data to go on.

The analyst is maintaining his conservative estimates but is encouraged by ACADIA confirming it is now on 99% + of targeted MEDICARE formularies, consistent with NUPLAZID being in a protected class. The company also reports it is on 25-30% of commercial formularies targeted, with more complete progress expected on that front by YE16.

No change to the price target of $44.

At a recent conference, ACADIA confirmed it is now on 99% + of targeted MEDICARE formularies, consistent with NUPLAZID being in a protected class. The company also reports it is on 25-30% of commercial formularies targeted, with more complete progress expected on that front by YE16. ACADIA believes most plans require confirmation of PDP diagnosis in terms of prior authorization, but has not seen unanticipated restrictions from most payers beyond that.

For an analyst ratings summary and ratings history on Acadia Pharmaceuticals click here. For more ratings news on Acadia Pharmaceuticals click here.

Shares of Acadia Pharmaceuticals closed at $31.81 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Related Entities

Piper Jaffray, Earnings, Charles Duncan

Add Your Comment